VEGFD and lymphangioleiomyomatosis: First, due to the retrospective nature of our work, we did not determine any biomarker, such as vascular endothelial growth factor-D (VEGF-D) at time of first HRTC, which demonstrated a potential clinical utility in reaching a diagnosis of LAM [46].